FDA OKs Talquetamab, a First-in-Class Multiple Myeloma Drug

The approval follows a series of market withdrawals for other multiple myeloma drugs that initially received accelerated FDA approval.

Related Keywords

Michael Andreini , Janssen Biotech Inc , Drug Administration , Glaxosmithkline , Myeloma Research Foundation , Janssen Biotech , Tecvayli Talvey Risk Evaluation , Mitigation Strategy , Multiple Myeloma Research Foundation , Medwatch Reporting System , Multiple Myeloma , Myeloma , Plasma Cell Myeloma , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Refractory , Leukemia , Risk Evaluation And Mitigation Strategies Rems , Otolaryngology , Nt Ears , Nose , Throat , Upper Respiratory Infection , Dry Mouth , Xerostomia , Alabama , Biomedical Technology , Biotechnology , Blood , Cancer , Alignant Neoplasia , Arcinoma , Cytokines , Dentistr ,